Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial

Gene Therapy

Volumn 7, Issue 10, 2000, Pages 867-874

  Markert, J M ^a   Medlock, M D ^d,g   Rabkin, S D ^d   Gillespie, G Y ^a,b   Todo, T ^d   Hunter, W D ^d   Palmer, C A ^c   Feigenbaum, F ^d   Tornatore, C ^d   Tufaro, F ^e,f   Martuza, R L ^d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NeuroVir Therapeutics Inc   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

Author keywords

Anaplastic astrocytoma; Gene therapy; Glioblastoma; HSV; Human

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENCEPHALITIS; FEMALE; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

AOTUS NANCYMAAE; HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 12944315014     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301205     Document Type: Article

References (23)

1. Walker MD et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl J Med 1980; 303: 1323-1329.
2. Subach BR et al Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999; 45: 17-22; discussion 22-23.
3. Prados MD et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 1992; 23: 3-8.
4. Chamberlain MC, Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol 1999; 43: 71-78.
5. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
6. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1995; 1: 938-943.
7. Hunter WD et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999; 73: 6319-6326.
8. Sundaresan P et al. Attenuated, replication competent herpes simplex virus type I mutant G207: safety evaluation in mice. J Virol 2000; 74: 3832-3841.
9. Yazaki T et al. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55: 4752-4756.
10. Toda M et al. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457-4464.
11. Todo T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741-2755.
12. Peck DJ et al. Cerebral tumor volume calculations using planimetric and eigenimage analysis (see comments). Med Phys 1996; 23: 2035-2042.
13. Rampling R et al. Therapeutic replication-competent herpes virus (letter; comment). Nature Med 1998; 4: 133.
14. Choucair AK et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986; 65: 654-658.
15. Pasquier B et al. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer 1980; 45: 112-125.
16. Hashido M et al. Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan. Microbiol Immunol 1999; 43: 177-180.
17. Cobbs C, Markert J. Gene therapy of glioma: a review. Perspectives Neurol Surg 1999; 10: 1-20.
18. Whitley RJ, Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM (eds). Field Virology. Lippincott-Raven Publishers: New York, 1996, pp 2297-2342.
19. Markert JM et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
20. Mineta T et al. CNS tumor therapy by attenuated herpes simplex viruses. Gene Therapy 1994; 1(Suppl. 1): S78.
21. Toda M et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-393.
22. Andreansky S et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Therapy 1998; 5: 121-130.
23. Common Toxicity Criteria. National Institutes of Health, National Cancer Institute: Bethesda, 1984.